# IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

> **NCT02556593** · PHASE2 · TERMINATED · sponsor: **Sun Yat-sen University** · enrollment: 12 (actual)

## Conditions studied

- Non-Small Cell Lung Carcinoma

## Interventions

- **RADIATION:** IMRT
- **RADIATION:** WBRT
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT02556593
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556593, "IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02556593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*